EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSPTIG00000015311
Gene Symbol: CACNA1D
2 Cross references
281 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSPTIG00000005747
Gene Symbol: CACNA1E
2 Cross references
294 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSPTIG00000016408
Gene Symbol: CACNA1F
2 Cross references
178 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSPTIG00000010136
Gene Symbol: CACNA1G
1 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSPTIG00000010077
Gene Symbol: CACNA1H
2 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSPTIG00000020353
Gene Symbol: CACNA1I
2 Cross references
264 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSPTIG00000021055
Gene Symbol: CACNA1S
2 Cross references
259 Possible Orthologues:

Carbonic Anhydrase 1

Ensembl ID : ENSPTIG00000008321
Gene Symbol: CA1
2 Cross references
285 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSPTIG00000008179
Gene Symbol: CA12
2 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSPTIG00000007600
Gene Symbol: CA13
2 Cross references
288 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSPTIG00000020798
Gene Symbol: CA14
2 Cross references
210 Possible Orthologues:

Carbonic Anhydrase 2

Ensembl ID : ENSPTIG00000010298
Gene Symbol: CA2
2 Cross references
282 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).